Cardiometabolic effects of sequential prolactin states in dopamine agonist-treated prolactinoma patients: a retrospective longitudinal study
Authors' conclusion
Normalization of prolactin concentrations was associated with significant improvements in body weight, BMI, and total cholesterol concentrations. In contrast, no significant cardiometabolic improvements were detected following the subsequent development of treatment-induced hypoprolactinemia. Furthermore, the magnitude of prolactin reduction was not independently associated with changes in anthropometric or metabolic parameters after multivariable adjustment.
Study context
- Population
- Prolactinoma patients treated with cabergoline who sequentially transitioned from hyperprolactinemia to normoprolactinemia to hypoprolactinemia, 19 tertiary hospitals in Spain
- Participants
- 47 patients
- Exposure
- Sequential prolactin states during cabergoline therapy: Hyperprolactinemia (HyperPRL) vs normoprolactinemia (NormoPRL) vs hypoprolactinemia (HypoPRL)
- Outcome
- Longitudinal changes in anthropometric, hemodynamic and metabolic parameters across sequential prolactin states
Methodological detailsmulticentre
- Multicentre
Main finding
As reported in the abstract
| Group | Value | BMI (kg/m²) | Total cholesterol (mg/dL) |
|---|---|---|---|
| HyperPRL | mean 80.4 (SD 23.6) kg | 29.3 ± 7.4 | 194.3 ± 36.5 |
| NormoPRL | mean 78.7 (SD 22.8) kg | 28.4 ± 7.3 | 178.7 ± 34.8 |
Value
BMI (kg/m²)
Total cholesterol (mg/dL)
- NormoPRL vs HyperPRL: P = 0.009 — body weight
- NormoPRL vs HyperPRL: P = 0.034 — BMI
- NormoPRL vs HyperPRL: P = 0.006 — total cholesterol
Observational data: associations, not effects.
Further findings
Triglycerides across prolactin states
- Trend toward reduction across prolactin states, with a significant decrease between HyperPRL and NormoPRL
Cardiometabolic parameters: NormoPRL to HypoPRL
- No additional cardiometabolic improvements after transition from NormoPRL to HypoPRL
Generalized estimating equation (GEE) analyses adjusted for age, sex and initial cabergoline dose
- Significant longitudinal reductions in body weight and total cholesterol confirmed; unchanged in sensitivity analyses also accounting for treatment duration
Prolactin reduction and metabolic change
- Weak inverse association of % prolactin reduction with body weight change in exploratory analyses; no independent associations after multivariable adjustment
Original publication
Composed by AI from the published abstract and checked against it. How Briefs are made →